Research Article
BibTex RIS Cite

Evaluation Of Hepcidin And Iron Concentrations With Liver And Kidney Functions In Beta-Thalassemia Patients

Year 2025, Volume: 46 Issue: 1, 8 - 12, 25.03.2025

Othman R Al Samarraı , Hazem Mohammed Abd , Mohammed Hameed Mahal , Ali Rasheed Hameed Al Samarrai

https://doi.org/10.17776/csj.1562338

Abstract

The goal of this research was to estimate the concentrations of iron and hepcidin with liver and kidney functions in beta-thalassemia patients, the study involved the collection of 80 blood samples from both sexes, and the samples were distributed into 45 samples for beta thalassemia patients, their ages ranged between 15-25 years, the samples were collected from the Thalassemia Specialization Center in Baquba General Hospital, and 35 blood samples for healthy people as a control group, their ages extended from 15 to 25. years, during the period from the beginning of March 2023 until the end of May 2023. The study's findings revealed a considerable increase in the concentrations of hepcidin and iron in patients group compared with the healthy ones. It also displayed a significant reduce in the patients' albumin and creatinine concentrations as compared with healthy group, while the results here were no significant variations in total protein, urea and uric acid levels.

Keywords

Beta-thalassemia Hepcidin Iron Liver Kidney

References

  • [1] Oltean A., & IM C.. Mentzer Index in pediatric thalassemia trait, Jurnalul Pediatrului, 23 (89-90) (2020) 35-40.
  • [2] JLT J. M. B. Lubert Stryer editor, BIOCHEMISTRY. 5th ed. W. H. Freeman, (2002) 596. ISBN-10: 0716746840, ISBN-13: 978-0716746843.
  • [3] Rivella S., β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies, Haematologica, 100 (4) (2015) 418.
  • [4] Bajwa H., Basit H., Thalassemia, StatPearls Publishing, Treasure Island (FL), 2023.
  • [5] Mathur S., Sutton J., Personalized medicine could transform healthcare, Biomedical Reports, 7 (1) (2017) 3-5.
  • [6] Danjou F., Anni F., Galanello R., Beta-thalassemia: from genotype to phenotype, Haematologica, 96 (11) (2011) 1573.
  • [7] Prathyusha K., Venkataswamy M., Goud K. S., Ramanjaneyulu K., Himabindu J., Raj K. S., Thalassemia-A Blood Disorder, its Cause, Prevention and Management, Research Journal of Pharmaceutical Dosage Forms and Technology, 11 (3) (2019) 186-190.
  • [8] Casu C., Oikonomidou P. R., Chen H., Nandi V., Ginzburg Y., Prasad P., Rivella S., Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera, Blood, The Journal of the American Society of Hematology, 128 (2) (2016) 265-276.
  • [9] Rauf A., Shariati M. A., Khalil A. A., Bawazeer S., Heydar M., Plygun S., Aljohani A. S. Hepcidin, an overview of biochemical and clinical properties, Steroids, 160 (2020) 108661.
  • [10] Keohane E. M., Otto C. N., Walenga J. M., Rodak's Hematology-E-Book: Rodak's Hematology-E-Book, Elsevier Health Sciences, (2019).
  • [11] Papanikolaou G., Tzilianos M., Christakis J. I., Bogdanos D., Tsimirika K., MacFarlane J., Nemeth E. Hepcidin in iron overload disorders, Blood, 105 (10) (2005) 4103-4105.
  • [12] Abd H. M., Al Samarrai O. R., Evaluation of hepcidin, ferritin and iron levels with liver enzymes of β-thalassemia patients in Diyala governorate, Iraq, In AIP Conference Proceedings, 2450 (1). (2022) AIP Publishing.
  • [13] Goodnough L. T., Iron deficiency syndromes and iron‐restricted erythropoiesis (CME), Transfusion, 52 (7) (2012) 1584-1592.
  • [14] Hasoon I. G., Shani W. S., Radi A. M., The association of hepcidin with some inflammatory markers in β-thalassemia major patients of Basrah Province, EurAsian Journal of BioSciences, 14 (2) (2020) 7285-7289.
  • [15] Neufeld E. J., Update on iron chelators in thalassemia, Hematology 2010, The American Society of Hematology Education Program Book, 2010 (1) (2010) 451-455.
  • [16] Kosman D. J., Redox cycling in iron uptake, efflux, and trafficking, Journal of Biological Chemistry, 285 (35) (2010) 26729-26735.
  • [17] Hosen M. B., Karmokar N. C., Karim M. F., Al Mahmud R., Mesbah, M., Association of AST, ALT, ALB and total protein with beta-thalassemia in Bangladeshi population, International Journal, 3 (1) (2015) 991-995.
  • [18] Abd I. K., Zainal I. G., Assessment of biochemical parameters and study its correlation in ß-Thalassemia major patients and healthy controls in Kirkuk City, Iraq, Medical Journal of Babylon, 17 (2) (2020) 172-176.
  • [19] Malik A. M., Malik E. M., Al-Shammaa N. M., Al-Rubaei Z. M., A Comparative Biochemical Study of Proteins Profile in Iraqi Children and Adolescent with β–Thalassemia, Iraqi J. Pharm. Sci., 19 (2) (2010) 19-23.
  • [20] Walter P. B., Macklin E. A., Porter J., Evans P., Kwiatkowski J. L., Neufeld E. J., Harmatz, P., Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial, Haematologica, 93 (6) (2008) 817-825.
  • [21] Pieniazek A., Gwozdzinski L., Zbrog Z., Gwozdzinski K., Alterations in conformational state of albumin in plasma in chronic hemodialyzed patients, PLoS One, 13 (3) (2018) e0192268.
  • [22] Taverna M., Marie A. L., Mira J. P., Guidet B., Specific antioxidant properties of human serum albumin, Annals of Intensive Care, 3 (2013) 1-7.
  • [23] Oki S., Toiyama Y., Okugawa Y., Shimura T., Okigami M., Yasuda H., Kusunoki M., Clinical burden of preoperative albumin-globulin ratio in esophageal cancer patients, The American Journal of Surgery, 214 (5) (2017) 891-898.
  • [24] Althanoon Z. A., Alkazzaz N. A., Comparison of The Effects of Deferasirox And Deferoxamine On Uric Acid And Renal Function In Patients with Beta Thalassemia, Systematic Reviews in Pharmacy, 11 (11) (2020).
  • [25] Ghazala M. M., Abdellateif S. S., Taher M. M. S., Abdelmohsen E. A., Bakheet O. H., Assem A. A. A., Serum hepcidin and growth differentiation factor 15 in patients with β-thalassemia and its relation to blood transfusion, Al-Azhar International Medical Journal, 2 (3) (2021) 43-48.
  • [26] Shanaki M., Ehteram H., Nasiri H., Azad M., Kouhkan F., Pakzad R., Mobarra N., Assessment of Liver and Kidney Functional Parameters along with oxidative Stress and Inflammatory Biomarker in Patients with β-Thalassemia major, Iranian Journal of Pediatric Hematology and Oncology, 6 (4) (2016) 249-260.
  • [27] Jalali A., Khalilian H., Ahmadzadeh A., Sarvestani S., Rahim F., Zandian K., Asar S., Renal function in transfusion-dependent pediatric beta-thalassemia major patients, Hematology, 16 (4) (2011) 249-254.
  • [28] Sadeghi-Bojd S., Hashemi M., Karimi M., Renal tubular function in patients with beta-thalassaemia major in Zahedan, southeast Iran, Singapore Med. J., 49 (5) (2008) 410-2.
  • [29] Majeed A. M. H., Hameed O. R., Effect of endothelin-1, Vimentin and some biochemical variables on men with type 2 diabetes mellitus, diabetic patients with hypertension, and diabetic patients with renal impairment, Samarra Journal of Pure and Applied Science, 4 (3) (2022) 61-78.
  • [30] Younus Z. M., Alhially Y. A. H., Bashi A. Y. D., Evaluation of conventional renal function tests in β-thalassemia major patients in Nineveh province, Tikrit Journal of Pharmaceutical Sciences, 8(1) (2012) 6-14.

Year 2025, Volume: 46 Issue: 1, 8 - 12, 25.03.2025

Othman R Al Samarraı , Hazem Mohammed Abd , Mohammed Hameed Mahal , Ali Rasheed Hameed Al Samarrai

https://doi.org/10.17776/csj.1562338

Abstract

References

  • [1] Oltean A., & IM C.. Mentzer Index in pediatric thalassemia trait, Jurnalul Pediatrului, 23 (89-90) (2020) 35-40.
  • [2] JLT J. M. B. Lubert Stryer editor, BIOCHEMISTRY. 5th ed. W. H. Freeman, (2002) 596. ISBN-10: 0716746840, ISBN-13: 978-0716746843.
  • [3] Rivella S., β-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies, Haematologica, 100 (4) (2015) 418.
  • [4] Bajwa H., Basit H., Thalassemia, StatPearls Publishing, Treasure Island (FL), 2023.
  • [5] Mathur S., Sutton J., Personalized medicine could transform healthcare, Biomedical Reports, 7 (1) (2017) 3-5.
  • [6] Danjou F., Anni F., Galanello R., Beta-thalassemia: from genotype to phenotype, Haematologica, 96 (11) (2011) 1573.
  • [7] Prathyusha K., Venkataswamy M., Goud K. S., Ramanjaneyulu K., Himabindu J., Raj K. S., Thalassemia-A Blood Disorder, its Cause, Prevention and Management, Research Journal of Pharmaceutical Dosage Forms and Technology, 11 (3) (2019) 186-190.
  • [8] Casu C., Oikonomidou P. R., Chen H., Nandi V., Ginzburg Y., Prasad P., Rivella S., Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera, Blood, The Journal of the American Society of Hematology, 128 (2) (2016) 265-276.
  • [9] Rauf A., Shariati M. A., Khalil A. A., Bawazeer S., Heydar M., Plygun S., Aljohani A. S. Hepcidin, an overview of biochemical and clinical properties, Steroids, 160 (2020) 108661.
  • [10] Keohane E. M., Otto C. N., Walenga J. M., Rodak's Hematology-E-Book: Rodak's Hematology-E-Book, Elsevier Health Sciences, (2019).
  • [11] Papanikolaou G., Tzilianos M., Christakis J. I., Bogdanos D., Tsimirika K., MacFarlane J., Nemeth E. Hepcidin in iron overload disorders, Blood, 105 (10) (2005) 4103-4105.
  • [12] Abd H. M., Al Samarrai O. R., Evaluation of hepcidin, ferritin and iron levels with liver enzymes of β-thalassemia patients in Diyala governorate, Iraq, In AIP Conference Proceedings, 2450 (1). (2022) AIP Publishing.
  • [13] Goodnough L. T., Iron deficiency syndromes and iron‐restricted erythropoiesis (CME), Transfusion, 52 (7) (2012) 1584-1592.
  • [14] Hasoon I. G., Shani W. S., Radi A. M., The association of hepcidin with some inflammatory markers in β-thalassemia major patients of Basrah Province, EurAsian Journal of BioSciences, 14 (2) (2020) 7285-7289.
  • [15] Neufeld E. J., Update on iron chelators in thalassemia, Hematology 2010, The American Society of Hematology Education Program Book, 2010 (1) (2010) 451-455.
  • [16] Kosman D. J., Redox cycling in iron uptake, efflux, and trafficking, Journal of Biological Chemistry, 285 (35) (2010) 26729-26735.
  • [17] Hosen M. B., Karmokar N. C., Karim M. F., Al Mahmud R., Mesbah, M., Association of AST, ALT, ALB and total protein with beta-thalassemia in Bangladeshi population, International Journal, 3 (1) (2015) 991-995.
  • [18] Abd I. K., Zainal I. G., Assessment of biochemical parameters and study its correlation in ß-Thalassemia major patients and healthy controls in Kirkuk City, Iraq, Medical Journal of Babylon, 17 (2) (2020) 172-176.
  • [19] Malik A. M., Malik E. M., Al-Shammaa N. M., Al-Rubaei Z. M., A Comparative Biochemical Study of Proteins Profile in Iraqi Children and Adolescent with β–Thalassemia, Iraqi J. Pharm. Sci., 19 (2) (2010) 19-23.
  • [20] Walter P. B., Macklin E. A., Porter J., Evans P., Kwiatkowski J. L., Neufeld E. J., Harmatz, P., Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial, Haematologica, 93 (6) (2008) 817-825.
  • [21] Pieniazek A., Gwozdzinski L., Zbrog Z., Gwozdzinski K., Alterations in conformational state of albumin in plasma in chronic hemodialyzed patients, PLoS One, 13 (3) (2018) e0192268.
  • [22] Taverna M., Marie A. L., Mira J. P., Guidet B., Specific antioxidant properties of human serum albumin, Annals of Intensive Care, 3 (2013) 1-7.
  • [23] Oki S., Toiyama Y., Okugawa Y., Shimura T., Okigami M., Yasuda H., Kusunoki M., Clinical burden of preoperative albumin-globulin ratio in esophageal cancer patients, The American Journal of Surgery, 214 (5) (2017) 891-898.
  • [24] Althanoon Z. A., Alkazzaz N. A., Comparison of The Effects of Deferasirox And Deferoxamine On Uric Acid And Renal Function In Patients with Beta Thalassemia, Systematic Reviews in Pharmacy, 11 (11) (2020).
  • [25] Ghazala M. M., Abdellateif S. S., Taher M. M. S., Abdelmohsen E. A., Bakheet O. H., Assem A. A. A., Serum hepcidin and growth differentiation factor 15 in patients with β-thalassemia and its relation to blood transfusion, Al-Azhar International Medical Journal, 2 (3) (2021) 43-48.
  • [26] Shanaki M., Ehteram H., Nasiri H., Azad M., Kouhkan F., Pakzad R., Mobarra N., Assessment of Liver and Kidney Functional Parameters along with oxidative Stress and Inflammatory Biomarker in Patients with β-Thalassemia major, Iranian Journal of Pediatric Hematology and Oncology, 6 (4) (2016) 249-260.
  • [27] Jalali A., Khalilian H., Ahmadzadeh A., Sarvestani S., Rahim F., Zandian K., Asar S., Renal function in transfusion-dependent pediatric beta-thalassemia major patients, Hematology, 16 (4) (2011) 249-254.
  • [28] Sadeghi-Bojd S., Hashemi M., Karimi M., Renal tubular function in patients with beta-thalassaemia major in Zahedan, southeast Iran, Singapore Med. J., 49 (5) (2008) 410-2.
  • [29] Majeed A. M. H., Hameed O. R., Effect of endothelin-1, Vimentin and some biochemical variables on men with type 2 diabetes mellitus, diabetic patients with hypertension, and diabetic patients with renal impairment, Samarra Journal of Pure and Applied Science, 4 (3) (2022) 61-78.
  • [30] Younus Z. M., Alhially Y. A. H., Bashi A. Y. D., Evaluation of conventional renal function tests in β-thalassemia major patients in Nineveh province, Tikrit Journal of Pharmaceutical Sciences, 8(1) (2012) 6-14.
There are 30 citations in total.

Details

Primary Language English
Subjects Analytical Biochemistry
Journal Section Natural Sciences
Authors

Othman R Al Samarraı 0000-0002-1487-4054

Hazem Mohammed Abd 0000-0002-8661-2985

Mohammed Hameed Mahal 0000-0002-7207-3140

Ali Rasheed Hameed Al Samarrai 0000-0001-9963-4449

Publication Date March 25, 2025
Submission Date October 6, 2024
Acceptance Date January 22, 2025
Published in Issue Year 2025Volume: 46 Issue: 1

Cite

APA Al Samarraı, O. R., Abd, H. M., Mahal, M. H., Al Samarrai, A. R. H. (2025). Evaluation Of Hepcidin And Iron Concentrations With Liver And Kidney Functions In Beta-Thalassemia Patients. Cumhuriyet Science Journal, 46(1), 8-12. https://doi.org/10.17776/csj.1562338
 Download Cover Image